Liquid Biopsy Market Projected to Reach USD 15 Billion by 2030, Driven by Advancements in Non-Invasive Cancer Diagnostics

According to a report by Next Move Strategy Consulting, the global liquid biopsy market was valued at USD 5 billion in 2022 and is projected to reach USD 15 billion by 2030, reflecting a compound annual growth rate (CAGR) of 16% from 2023 to 2030.

Get Your FREE Sample Now!

Market Segmentation and Dynamics

The liquid biopsy market is segmented based on product and service, cancer type, sampling type, circulating biomarker, technology, application, and end user:

• Product and Service: Assay Kits, Instruments, Reagents, and Services
• Cancer Type: Lung, Colorectal, Breast, Liver, Prostate, and Others
• Sampling Type: Blood, Urine, Saliva, and Others
• Circulating Biomarker: Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), Cell-Free DNA, Extracellular Vesicles (EVs), and Others
• Technology: Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Fluorescence in situ Hybridization (FISH), and Others
• Application: Cancer Therapeutic Application, Reproductive Health, and Others
• End User: Reference Laboratories, Hospitals and Physician Laboratories, Academic & Research Centers, and Others

The increasing prevalence of cancer and the growing demand for non-invasive diagnostic methods are driving the adoption of liquid biopsy technologies. These tests offer advantages such as reduced procedural complications, quicker diagnostic times, and the ability to monitor treatment response and detect minimal residual disease.

Geographical Insights

North America is expected to hold the dominant share of the liquid biopsy market, attributed to the presence of major healthcare providers, research institutions, and early adoption of advanced diagnostic technologies. The Asia-Pacific region is anticipated to witness significant growth due to the increasing healthcare infrastructure, rising cancer incidence, and expanding awareness about non-invasive diagnostic options.

Key Industry Players

Prominent companies operating in the liquid biopsy market include:

• Guardant Health
• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific Inc.
• Illumina, Inc.
• QIAGEN N.V.
• Biocept, Inc.
• Myriad Genetics, Inc.
• Bio-Rad Laboratories Inc.
• Natera, Inc.
• Epigenomics AG

These companies are focusing on product innovations, strategic partnerships, and acquisitions to enhance their market presence and cater to the growing demand for liquid biopsy solutions.

Emerging Trends

• Advancements in Sequencing Technologies: The development of next-generation sequencing (NGS) and digital PCR (dPCR) technologies is enhancing the sensitivity and specificity of liquid biopsy assays, enabling the detection of genetic alterations and biomarkers associated with cancer at higher levels of precision.
• Integration of Artificial Intelligence (AI) and Machine Learning (ML): AI and ML algorithms are being integrated into liquid biopsy platforms to enhance data analysis and interpretation, facilitating the identification of disease-specific biomarkers and prediction of patient outcomes, contributing to personalized treatment strategies.
• Expansion into Non-Cancer Applications: Liquid biopsies are finding applications beyond cancer diagnosis, including monitoring treatment response, detecting minimal residual disease, and identifying actionable mutations for targeted therapy. Emerging applications in prenatal screening, infectious disease detection, and transplantation monitoring are broadening the market scope.

Conclusion

The global liquid biopsy market is poised for substantial growth, driven by technological advancements and the increasing need for non-invasive diagnostic solutions. As industries continue to embrace digital transformation, the demand for efficient and scalable liquid biopsy solutions is expected to rise, presenting significant opportunities for market players.

About Next Move Strategy Consulting:

Next Move Strategy Consulting is a premier market research and management consulting firm that has been committed to provide strategically analyzed well documented latest research reports to its clients. The research industry is flooded with many firms to choose from, what makes Next Move different from the rest is its top-quality research and the obsession of turning data into knowledge by dissecting every Bit of it and providing fact-based research recommendation that is supported by information collected from over 500 million websites, paid databases, industry journals and one on one consultations with industry experts across a diverse range of industry sectors.

The high-quality customized research reports with actionable insights and excellent end-to-end customer service help our clients to take critical business decisions that enables them to move beyond time and have competitive edge in the industry. We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicates as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery Solutions that range from the pre consultation to after-sales services, provide an excellent client Experience and ensure right strategic decision making for businesses